astrazeneca glp 1 drug AstraZeneca's elecoglipron just posted some of the most closely watched Phase IIb data of the year and it landed at the right conference. Results from the VISTA and SOLSTICE trials, published simultaneously AstraZeneca's Oral GLP-1 Drug Elecoglipron
Description
Boyle, J
)
This review outlines the mechanistic pathways through which GLP-1 RAs influence BP, summarizes RCT evidence across relevant populations, and discusses implications for clinical practice and future research

Portha, B., Tourrel-Cuzin, C

Association between eating behavior patterns and the therapeutic efficacy of GLP-1 receptor agonists in individuals with type 2 diabetes: A multicenter prospective observational study

(Lausanne) 13 , 1033479 (2022)
